Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sebastian Fehlberg"'
Publikováno v:
British Journal of Pharmacology. 139:495-500
(1) Bisphenol A diglycidyl ether (BADGE) is a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) antagonist, which is able to induce apoptosis in tumor cells independently of PPAR-gamma in caspase-dependent and -independent manners. Additi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c97365a1838e6bb5aad745e57f0ca2f
https://doi.org/10.1038/sj.bjp.0705275
https://doi.org/10.1038/sj.bjp.0705275
Publikováno v:
Biochemical Journal. 362:573-578
Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors which are involved in many biological processes, such as regulation of cell differentiation, lipid metabolism, inflammation and cell death. PPARs consist of three f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2f87cbf1f102e2f572257fc48bd92b5
https://doi.org/10.1042/bj3620573
https://doi.org/10.1042/bj3620573
Autor:
Sebastian, Fehlberg, Sebastian, Eulenstein, Thomas, Lange, Dimosthenis, Andreou, Per-Ulf, Tunn
Publikováno v:
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 179
The treatment of malignant tumors involving the pelvic area is a challenging problem in musculoskeletal oncology due to the complex pelvic anatomy and the often large tumor size at presentation. The use of navigation systems has effectively increased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d665e34ac25c32fa5710159712edaf0e
https://pubmed.ncbi.nlm.nih.gov/19230540
https://pubmed.ncbi.nlm.nih.gov/19230540
Autor:
Andreou, Dimosthenis1 (AUTHOR) dimosthenis.andreou@helios-kliniken.de, Ruppin, Sebastian1 (AUTHOR), Fehlberg, Sebastian1 (AUTHOR), Pink, Daniel2 (AUTHOR), Werner, Mathias3 (AUTHOR), Tunn, Per-Ulf1 (AUTHOR)
Publikováno v:
Acta Orthopaedica. Dec2011, Vol. 82 Issue 6, p749-755. 7p.
Publikováno v:
British Journal of Pharmacology. Jun2003, Vol. 139 Issue 3, p495. 6p.
Autor:
Per-Ulf Tunn
Bone and soft tissue sarcomas represent only about 2% of all malignancies; however, their treatment – with the goal of curing the patient while preserving the functionality of the affected body part – can, unlike other malignancies, only be succe
